These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 27635672)

  • 1. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
    Ito T; Lee L; Jensen RT
    Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT; Kunz PL; Reidy-Lagunes DL
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug therapy for neuroendocrine tumours].
    Tóth M
    Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy for advanced pancreatic neuroendocrine tumors.
    Kulke MH
    Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
    Desai KK; Khan MS; Toumpanakis C; Caplin ME
    Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of neuroendocrine tumors.
    Chung C
    Am J Health Syst Pharm; 2016 Nov; 73(21):1729-1744. PubMed ID: 27769969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
    Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
    BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
    Giustina A; Mazziotti G; Maffezzoni F; Amoroso V; Berruti A
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1619-35. PubMed ID: 25060168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
    Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.
    Ito T; Jensen RT
    Expert Opin Pharmacother; 2021 Apr; 22(6):685-693. PubMed ID: 33131345
    [No Abstract]   [Full Text] [Related]  

  • 18. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.
    Ruggeri RM; Benevento E; De Cicco F; Fazzalari B; Guadagno E; Hasballa I; Tarsitano MG; Isidori AM; Colao A; Faggiano A;
    J Endocrinol Invest; 2023 Feb; 46(2):213-234. PubMed ID: 36038743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.
    Sood A; Munir M; Syed O; Mehta V; Kaur R; Kumar A; Sridhar A; Sood A; Gupta R
    Expert Opin Drug Saf; 2024 Aug; 23(8):949-957. PubMed ID: 38847075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.